%PDF-1.4
%
1 0 obj
<>>>
endobj
2 0 obj
<>stream
2017-07-17T12:28:25+05:30
2017-07-17T12:28:25+05:30
2017-07-17T12:28:25+05:30
Adobe InDesign CS6 (Macintosh)
uuid:1a2a1927-40e4-ca44-bcf0-c7f5369c6f27
xmp.did:01801174072068118DBB881A9EDFAAFA
xmp.id:86C2432617206811822A9B203D24B917
proof:pdf
converted
from application/x-indesign to application/pdf
Adobe InDesign CS6 (Macintosh)
/
2017-07-17T12:28:25+05:30
xmp.iid:4075A09C09206811822A9B203D24B917
xmp.did:01801174072068118DBB881A9EDFAAFA
xmp.did:01801174072068118DBB881A9EDFAAFA
default
application/pdf
Adobe PDF Library 10.0.1
False
endstream
endobj
5 0 obj
<>
endobj
3 0 obj
<>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[9.0 9.0 621.0 801.0]/Type/Page>>
endobj
8 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[9.0 9.0 621.0 801.0]/Type/Page>>
endobj
9 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[9.0 9.0 621.0 801.0]/Type/Page>>
endobj
10 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[9.0 9.0 621.0 801.0]/Type/Page>>
endobj
11 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[9.0 9.0 621.0 801.0]/Type/Page>>
endobj
12 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[9.0 9.0 621.0 801.0]/Type/Page>>
endobj
44 0 obj
<>stream
q
/GS0 gs
/Fm0 Do
Q
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
11 0 0 11 573.9999 54.4294 Tm
(49)Tj
ET
q
0 g
/GS0 gs
/Fm1 Do
Q
BT
/T1_0 1 Tf
10 0 0 10 45 698.2501 Tm
(31.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
-0.031 Tw 0.58 0 Td
[(Rahe-Me)15(y)19.7(er N)24.9(, Ber)17.9(ger C, )29.8(W)39.8(ittmann M, et al. Reco)44.9(v)14.9(er)-19.7(y from )]TJ
0.104 Tw 0 -1.2 TD
[(prolonged )0.5(deep )0.6(rocuronium-induced )0.5(neuromuscular )0.6(b)19.8(lock)]TJ
0 Tw (-)Tj
-0.066 Tw T*
[(ade: )55.1(A randomized comparison of sug)4.9(ammade)14.9(x re)24.9(v)14.9(ersal with )]TJ
0 Tw T*
[(spontaneous reco)45(v)14.9(er)-19.8(y)85(. )]TJ
/T1_2 1 Tf
(Anaesthesist )Tj
/T1_1 1 Tf
(2015;64\(7\):506-512.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(32.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
-0.003 Tw 0.58 0 Td
[(W)99.9(eek)9.8(es G, Ha)34.9(y)19.8(es N)24.9(, Bo)39.7(w)35(en M. Re)24.9(v)14.9(ersal of prolonged rocu)]TJ
0 Tw (-)Tj
0.22 Tw T*
[(ronium neuromuscular b)19.8(lockade with sug)4.9(ammade)14.9(x in an )]TJ
-0.028 Tw T*
[(obstetric patient with transv)14.9(erse m)39.8(y)19.8(elitis. )]TJ
/T1_2 1 Tf
[(Int J Obstet )59.9(Anesth )]TJ
/T1_1 1 Tf
0 Tw T*
(2010;19\(3\):333-336.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(33.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.037 Tw 0.58 0 Td
[(de Menezes CC, P)39.8(ece)14.9(guini LA, Silv)24.9(a ED)59.8(, Simoes CM. Use )]TJ
0.215 Tw T*
[(of )0.5(sug)4.9(ammade)15(x )0.5(after )0.6(neostigmine )0.5(incomplete )0.6(re)24.9(v)14.9(ersal )0.6(of )]TJ
0.431 Tw T*
[(rocuronium-induced neuromuscular b)19.8(lockade. )]TJ
/T1_2 1 Tf
[(Re)14.9(v Br)44.9(as )]TJ
0 Tw T*
(Anestesiol )Tj
/T1_1 1 Tf
(2012;62\(4\):543-547.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(34.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.201 Tw 0.58 0 Td
[(Lenz )54.7(A, Hill G, )29.5(White PF)129.9(. Emer)17.9(genc)14.9(y use of sug)4.9(amma)]TJ
0 Tw (-)Tj
0.124 Tw T*
[(de)14.9(x after f)-9.8(ailure of standard re)24.9(v)14.9(ersal dr)-19.8(ugs. )]TJ
/T1_2 1 Tf
0.065 Tw [(Anesth Analg)14.9(. )]TJ
/T1_1 1 Tf
0 Tw T*
(2007;104\(3\):585-586.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(35.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.068 Tw 0.58 0 Td
[(Bridion )0.5(product )0.5(infor)-19.7(mation. )]TJ
/T1_2 1 Tf
12.055 0 Td
[(Bridion )0.5(w)14.9(eb )0.5(site)14.9(.)]TJ
/T1_1 1 Tf
0 Tw ( )Tj
7.229 0 Td
[(http://www)89.9(.)]TJ
0.031 Tc -0.031 Tw -19.284 -1.2 Td
[(ema.europa.eu/docs/en_GB/document_librar)-19.9(y/EP)119.8(AR_-_)]TJ
0 Tc 0 Tw T*
[(Product_Infor)-19.7(mation/human/000885/WC500052310.pdf)]TJ
(.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(36.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.088 Tw 0.58 0 Td
[(Cammu G, de Kam PJ)59.8(, De Grae)25(v)14.9(e K, et al. Repeat dosing )]TJ
0.051 Tw T*
[(of rocuronium 1.2 mg kg-1 after re)24.9(v)14.9(ersal of neuromuscular )]TJ
0.016 Tw T*
[(b)19.8(lock b)24.9(y sug)4.9(ammade)15(x 4.0 mg kg-1 in anaesthetized health)29.8(y )]TJ
-0.073 Tw T*
[(v)19.8(olunteers: a modelling-based pilot study)85(. )]TJ
/T1_2 1 Tf
-0.133 Tw [(Br )-59.9(J Anaesth )]TJ
/T1_1 1 Tf
0 Tw 21.722 0 Td
(2010;)Tj
( )Tj
-21.722 -1.2 Td
(105\(4\):487-492.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(37.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
-0.018 Tw 0.58 0 Td
[(de Boer HD)59.9(, Driessen JJ)59.8(, v)24.9(an Egmond J)59.9(, Booij LH. Non-ste)]TJ
0 Tw (-)Tj
0.082 Tw T*
[(roidal )0.6(neuromuscular )0.5(b)19.8(locking )0.6(agents )0.5(to )0.6(re-estab)19.8(lish )0.6(paral)]TJ
0 Tw (-)Tj
0.259 Tw T*
[(ysis after re)25(v)14.9(ersal of rocuronium-induced neuromuscular )]TJ
-0.099 Tw T*
[(b)19.8(lock with sug)4.9(ammade)15(x. )]TJ
/T1_2 1 Tf
-0.159 Tw [(Can )-60.1(J Anaesth )]TJ
/T1_1 1 Tf
0 Tw 15.667 0 Td
(2008;55\(2\):124-125;)Tj
( )Tj
-15.667 -1.2 Td
[(author repl)25(y 125-126.)]TJ
/T1_0 1 Tf
-1.8 -1.2 Td
(38.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.124 Tw 0.58 0 Td
[(Cammu G, Coar)-19.7(t D)59.8(, De Grae)25(v)14.9(e K, Beelen R. )0.5(Re)24.9(v)14.9(ersal of )]TJ
0.188 Tw T*
[(rocuronium-induced neuromuscular b)19.8(lock with s)]TJ
0 Tw [(ug)4.9(amma)]TJ
(-)Tj
0.231 Tw T*
[(de)14.9(x in hear)-19.8(t f)-9.7(ailure patients: a prospecti)25(v)14.8(e obser)-19.7(v)24.9(ational )]TJ
0 Tw T*
[(study)85(. )]TJ
/T1_2 1 Tf
-0.06 Tw [(Acta Anaesthesiol )-59.9(Belg )]TJ
/T1_1 1 Tf
0 Tw 12.049 0 Td
(2012;63\(2\):69-73.)Tj
/T1_0 1 Tf
-13.849 -1.2 Td
(39.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.082 Tw 0.58 0 Td
[(K)34.9(onishi J)59.8(, Suzuki )49.8(T)99.9(, K)34.9(ondo )89.9(Y)128.9(, Baba M, Og)4.9(a)39.8(w)24.9(a S. Rocuro)]TJ
0 Tw (-)Tj
0.137 Tw T*
[(nium and sug)4.9(ammade)14.9(x used ef)24.9(fecti)25(v)14.9(el)24.9(y for electrocon)39.9(vul)]TJ
0 Tw (-)Tj
0.179 Tw T*
[(si)24.9(v)14.9(e therap)29.8(y in a patient with Br)-19.7(ug)4.9(ada syndrome. )]TJ
/T1_2 1 Tf
(J ECT )Tj
/T1_1 1 Tf
0 Tw T*
(2012;28\(2\):e21-22.)Tj
/T1_0 1 Tf
-0.01 Tc 0.01 Tw -1.8 -1.2 Td
(40.)Tj
/Span<>> BDC
1.19 0 Td
( )Tj
EMC
/T1_1 1 Tf
-0.073 Tw 0.61 0 Td
[(de Kam PJ)59.8(, v)24.8(an K)24.9(uijk J)59.9(, Prohn M, )50(Thomsen )49.9(T)99.9(, P)39.8(eeters P)159.9(. Ef)24.9(fects)-10( )]TJ
-0.035 Tw T*
[(of sug)4.9(ammade)14.9(x doses up to 32 mg/kg alone or in combination)-10( )]TJ
0 Tw T*
[(with rocuronium or v)14.9(ecuronium on QTc prolong)4.9(ation: a thor)]TJ
0 Tc 23.667 0 Td
(-)Tj
-0.01 Tc -23.667 -1.2 Td
[(ough QTc study)85(. )]TJ
/T1_2 1 Tf
[(Clin Drug In)39.8(vestig )]TJ
/T1_1 1 Tf
0.01 Tw (2010;30\(9\):599-611.)Tj
/T1_0 1 Tf
0 Tc 0 Tw -1.8 -1.2 Td
(41.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.148 Tw 0.58 0 Td
[(de Kam PJ)59.9(, v)24.9(an K)24.9(uijk J)59.8(, Smeets J)59.8(, )49.6(Thomsen )49.7(T)99.9(, P)39.8(eeters P)159.9(. )]TJ
0.329 Tw T*
[(Sug)4.9(ammade)14.9(x is not associated with QT/QTc )0.5(prolong)4.8(a)]TJ
0 Tw (-)Tj
0.093 Tw T*
[(tion: methodolo)24.9(gy aspects of an intra)34.9(v)14.9(enous mo)19.8(xi\036o)19.8(xacin-)]TJ
/Span<>> BDC
( )Tj
EMC
0.14 Tw T*
[(controlled thorough QT study)85(. )]TJ
/T1_2 1 Tf
[(Int J Clin Pharmacol )60.1(Ther )]TJ
/T1_1 1 Tf
0 Tw T*
(2012;50\(8\):595-604.)Tj
/T1_0 1 Tf
26.4 52.791 Td
(42.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.292 Tw 0.58 0 Td
[(Y)139.9(assen K, Lotfy M, )54.6(Abdulatif M, )54.5(A\037\037 M, El K)35(om S. )]TJ
0.657 Tw T*
[(Sug)4.9(ammade)14.9(x v)14.9(ersus neostigmine for antagonism of )]TJ
0.353 Tw /Span<>> BDC
T*
( )Tj
EMC
0 0 TD
[(rocuronium-induced neuromuscular b)19.8(lockade in patients )]TJ
-0.025 Tw 0 -1.2 TD
[(with )0.5(li)24.9(v)14.9(er cir)-29.7(rhosis )0.5(under)17.8(going li)24.9(v)14.9(er )0.5(resection: )0.5(a )0.5(randomized )]TJ
0 Tw T*
[(controlled study)85(. ClinicalT)35(rials.go)44.9(v)109.9(. 2015.)]TJ
/T1_0 1 Tf
-1.8 -1.2 Td
(43.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.327 Tw 0.58 0 Td
[(Joshi SB)29.8(, Upadh)29.8(ya)35(ya KV)200(, Manjulade)24.9(vi M. Comparison )]TJ
0.145 Tw T*
[(of )0.6(neostigmine )0.6(induced )0.5(re)25(v)14.9(ersal )0.6(of )0.5(v)14.9(ecuronium )0.6(in )0.6(nor)-19.8(mal )]TJ
0.293 Tw T*
[(w)34.9(eight, o)44.9(v)14.9(erw)34.9(eight and obese female patients. )]TJ
/T1_2 1 Tf
(Indian J )Tj
0 Tw T*
(Anaesth )Tj
/T1_1 1 Tf
(2015;59\(3\):165-170.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(44.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
-0.031 Tw 0.58 0 Td
[(Challan Belv)24.9(al )54.6(A, )49.5(T)34.9(ramoni G, )49.5(V)110.8(edrinne JM, Olagne E, )49.4(V)39.8(ign)]TJ
0 Tw (-)Tj
-0.007 Tw T*
[(eron )0.5(M. )0.6([The )0.5(use )0.5(of )0.6(sug)4.8(ammade)15(x )0.5(in )0.5(a )0.5(patient )0.6(with )0.5(m)39.8(yasthe)]TJ
0 Tw (-)Tj
T*
[(nia g)-19.8(ra)35(vis]. )]TJ
/T1_2 1 Tf
[(Ann F)54.9(r )59.9(Anesth Reanim )]TJ
/T1_1 1 Tf
(2012;31\(6\):569-570.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(45.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.58 0 Td
[(Garcia )50.2(V)200(, Diemunsch P)159.9(, Boet S. Use of rocuronium and sug)]TJ
(-)Tj
0.059 Tw T*
[(ammade)14.9(x for caesarean deli)24.9(v)14.9(er)-19.7(y in a patient with m)39.8(yasthe)]TJ
0 Tw (-)Tj
T*
[(nia g)-19.8(ra)35(vis. )]TJ
/T1_2 1 Tf
[(Int J Obstet )59.9(Anesth )]TJ
/T1_1 1 Tf
(2012;21\(3\):286-287.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(46.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.253 Tw 0.58 0 Td
[(Rudzka-No)39.9(w)24.9(ak )55.4(A, Piechota )0.5(M. )55.4(Anaesthetic )0.5(management )]TJ
0.111 Tw T*
[(of a patient with m)39.8(yasthenia g)-19.8(ra)35(vis for abdominal sur)17.8(ger)-19.8(y )]TJ
0 Tw T*
[(using sug)4.9(ammade)14.9(x. )]TJ
/T1_2 1 Tf
[(Ar)36.9(c)14.9(h Med Sci )]TJ
/T1_1 1 Tf
(2011;7\(2\):361-364.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(47.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.251 Tw 0.58 0 Td
[(Sungur Ulk)9.8(e Z, )89.9(Y)139.9(a)34.9(vr)-19.7(u )54.9(A, Camci E, Ozkan B)29.8(, )49.8(T)79.8(ok)9.8(er )54.9(A, )]TJ
0.09 Tw /Span<>> BDC
T*
( )Tj
EMC
0 0 TD
[(Senturk M. Rocuronium and sug)4.8(ammade)15(x in patients with )]TJ
0.08 Tw 0 -1.2 TD
[(m)39.8(yasthenia g)-19.8(ra)34.9(vis under)17.8(going th)29.8(ymectom)39.8(y)84.9(. )]TJ
/T1_2 1 Tf
0.02 Tw (Acta Anaesthe)Tj
0 Tw (-)Tj
T*
(siol Scand )Tj
/T1_1 1 Tf
(2013;57\(6\):745-748.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(48.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.09 Tw 0.58 0 Td
[(T)79.8(ak)9.8(eda )55.5(A, )0.5(Ka)39.8(w)24.9(amura )0.6(M, )0.5(Hama)35(ya )0.5(I, )0.5(Kitamura )0.5(H, )0.6(Muto )0.5(R, )]TJ
0.164 Tw T*
[(Mitono H. [Case of anesthesia for thoracoscopic th)29.8(ymec)]TJ
0 Tw (-)Tj
0.052 Tw T*
[(tom)39.8(y in a pediatric patient with m)39.8(yasthenia g)-19.7(ra)34.9(vis: re)25(v)14.9(ersal )]TJ
0.144 Tw T*
[(of rocuronium-induced neuromuscular b)19.8(lockade with sug)]TJ
0 Tw (-)Tj
T*
[(ammade)14.9(x]. )]TJ
/T1_2 1 Tf
(Masui )Tj
/T1_1 1 Tf
(2012;61\(8\):855-858.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(49.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.175 Tw 0.58 0 Td
[(Unterb)-4.8(uchner C, F)19.8(ink H, Blobner M. )50(The use of sug)4.9(am)]TJ
0 Tw (-)Tj
0.264 Tw T*
[(made)14.9(x in a patient with m)39.8(yasthenia g)-19.8(ra)35(vis. )]TJ
/T1_2 1 Tf
0 Tw (Anaesthesia )Tj
/T1_1 1 Tf
T*
(2010;65\(3\):302-305.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(50.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
-0.029 Tw 0.58 0 Td
[(Hettiarachchi G, Nguy)19.8(en D)59.8(, )29.6(W)49.8(u J)59.8(, et al. )49.6(T)79.9(o)19.7(xicolo)25(gy and dr)-19.8(ug )]TJ
0.031 Tw T*
[(deli)24.9(v)14.9(er)-19.7(y b)24.9(y cucurbit[n]uril type molecular containers. )]TJ
/T1_2 1 Tf
0 Tw (PLoS )Tj
T*
[(One)14.9(. )]TJ
/T1_1 1 Tf
(2010;5\(5\):e10514.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(51.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.279 Tw 0.58 0 Td
[(Hof)24.9(fmann U)79.8(, Grosse-Sundr)-19.7(up M, Eik)9.7(er)-19.7(mann-Haer)-19.7(ter K, )]TJ
0.218 Tw T*
(et)Tj
/Span<>> BDC
( )Tj
EMC
[(al. Calabadion: )55.1(A ne)24.9(w agent to re)25(v)14.8(erse the ef)25(fects of )]TJ
0.338 Tw T*
[(benzylisoquinoline and steroidal neuromuscular)19.9(-b)19.8(locking )]TJ
0 Tw T*
(agents. )Tj
/T1_2 1 Tf
[(Anesthesiolo)25(g)-19.8(y )]TJ
/T1_1 1 Tf
(2013;119\(2\):317-325.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(52.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.056 Tw 0.58 0 Td
[(Haer)-19.7(ter F)129.9(, Simons JC, F)49.8(oerster U)79.8(, et al. Comparati)24.9(v)14.9(e ef)25(fec)]TJ
0 Tw (-)Tj
0.249 Tw T*
[(ti)24.9(v)14.9(eness of calabadion and sug)4.9(ammade)15(x to re)24.9(v)14.9(erse non-)]TJ
0 Tw ( )Tj
-0.113 Tw T*
[(depolarizing neuromuscular)19.8(-b)19.8(locking agents. )]TJ
/Span<>> BDC
( )Tj
EMC
/T1_2 1 Tf
0 Tw 17.95 0 Td
[(Anesthesiolo)25(g)-19.8(y )]TJ
/T1_1 1 Tf
-17.95 -1.2 Td
(2015;123\(6\):1337-1349.)Tj
/T1_0 1 Tf
-1.8 -1.2 Td
(53.)Tj
/Span<>> BDC
1.22 0 Td
( )Tj
EMC
/T1_1 1 Tf
0.098 Tw 0.58 0 Td
[(Diaz-Gil )0.6(D)59.8(, )0.6(Haer)-19.8(ter )0.6(F)129.9(, )0.5(F)59.8(alcinelli )0.6(S, )0.6(et )0.5(al. )55.5(A )0.6(No)44.9(v)14.9(el )0.5(strate)15(gy )]TJ
0.149 Tw T*
[(to re)25(v)14.9(erse general anesthesia b)25(y sca)34.9(v)14.9(enging with the ac)14.9(y)]TJ
0 Tw (-)Tj
0.079 Tw T*
(clic cucurbit[n]uril-type molecular container Calabadion 2. )Tj
/T1_2 1 Tf
0 Tw T*
[(Anesthesiolo)25(g)-19.8(y )]TJ
/T1_1 1 Tf
(2016;125\(2\):333-345.)Tj
ET
endstream
endobj
33 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
BT
0 0 0 1 k
/GS0 gs
/T1_0 1 Tf
0 Tc 0 Tw 0 Ts 100 Tz 0 Tr 8 0 0 8 45 54.1778 Tm
(The Southwest Respiratory and Critical Care Chronicles 2017;5\(20\):44\226\
49)Tj
ET
endstream
endobj
34 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
0 0 0 1 K
0.5 w 4 M 0 j 0 J
/GS0 gs
q 1 0 0 1 45 68.8957 cm
0 0 m
540 0 l
S
Q
10 M
q 1 0 0 1 45 740.2762 cm
0 0 m
540 0 l
S
Q
BT
0 0 0 1 k
/TT0 1 Tf
0 Tc 0 Tw 0 Ts 100 Tz 0 Tr 8 0 0 8 45 751.5262 Tm
[(Sugammadex: )36.5(A)37.1( Neuromuscular Blockade )35.6(Agent Encapsulator)]TJ
/Span<>> BDC
( )Tj
EMC
63.942 0 Td
(Hurtado)Tj
ET
endstream
endobj
46 0 obj
<>
endobj
47 0 obj
<>
endobj
48 0 obj
<>stream
H\n0y
$JP@aZ(*iC~vHc8IQJM2yCS$ p
+:'6]3=f W8A_vf8
Ks7*L?ЃZ湴bڿ=$JnWs 8߰f0PƑKsp?86u&5ah6 )yGgȻmd4(Σ(u3挘s*ʩ4&>2|"s.X\4פ_M4kФAM4ׅ.qStqSs[E
us|9~
endstream
endobj
49 0 obj
<>stream
HlU TG!**bQTpנ"A
0AYDpW\:5bDE]] FYdF=sr;u{C">SV'y8lc|91%ة̽PadNk|&b̳X=tfq++-Sͱ'yKb&F\:Z3E&@^1>".ӳ^։ Iz3{v?qZd]W^/ 2ql[hFa*̢&l
Ja# 14!>]V` V@ ս̨4|uM4ֳwpܠa#WM6knt7hʣgzic~]vޣg}?`ǁ IȰ#>
9j>f0qR9*zظĩӒHM9k/Xh˖bk2֮[
?ߴy[m߱3+;gW/|W}oE9zŧy3gϝPrK7u;wPQ %8Ӂ`
:TZ'.flf4=y&w0L&GholUL^[W`?i|blb4'?~
=cz_UޕjqՆEU3*TUlȪXQHZ1§b߫w@L"ϱ[9pgxt9VO؆P)ט$"pPoQaU\C~Z5\G4c
qE